Autolus Therapeutics (NASDAQ:AUTL) Shares Gap Up Following Better-Than-Expected Earnings

Autolus Therapeutics plc (NASDAQ:AUTL)’s stock price gapped up prior to trading on Thursday after the company announced better than expected quarterly earnings. The stock had previously closed at $1.94, but opened at $2.01. Autolus Therapeutics shares last traded at $1.92, with a volume of 220,321 shares.

The company reported ($0.09) EPS for the quarter, beating the consensus estimate of ($0.21) by $0.12. The firm had revenue of $0.03 million during the quarter, compared to analyst estimates of $2.98 million.

Analyst Upgrades and Downgrades

Separately, Needham & Company LLC reaffirmed a “buy” rating and issued a $10.00 price target on shares of Autolus Therapeutics in a report on Monday, January 13th. Five analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock has a consensus rating of “Buy” and an average target price of $10.40.

Institutional Investors Weigh In On Autolus Therapeutics

Several large investors have recently modified their holdings of the stock. Jane Street Group LLC bought a new stake in Autolus Therapeutics during the 4th quarter worth approximately $26,000. Barclays PLC grew its position in Autolus Therapeutics by 1,094.3% during the 4th quarter. Barclays PLC now owns 11,859 shares of the company’s stock worth $28,000 after acquiring an additional 10,866 shares during the last quarter. Capstone Investment Advisors LLC bought a new stake in Autolus Therapeutics during the 3rd quarter worth approximately $51,000. Dumont & Blake Investment Advisors LLC bought a new stake in Autolus Therapeutics during the 4th quarter worth approximately $35,000. Finally, Arkadios Wealth Advisors bought a new stake in Autolus Therapeutics during the 4th quarter worth approximately $47,000. 72.83% of the stock is currently owned by institutional investors.

Autolus Therapeutics Stock Performance

The firm has a market capitalization of $445.71 million, a P/E ratio of -1.38 and a beta of 2.07. The stock has a 50-day moving average of $2.03 and a 200 day moving average of $2.93.

Autolus Therapeutics Company Profile

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma.